Friuli Valeria, Urru Claudia, Ferrara Chiara, Conti Debora Maria, Bruni Giovanna, Maggi Lauretta, Capsoni Doretta
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Department of Chemistry, Physical Chemistry Section & CSGI (Consorzio Interuniversitario per lo Sviluppo dei Sistemi a Grande Interfase), University of Pavia, 27100 Pavia, Italy.
Pharmaceutics. 2024 Feb 28;16(3):338. doi: 10.3390/pharmaceutics16030338.
The study focuses on the synthesis and characterization of Meloxicam-halloysite nanotube (HNT) composites as a viable approach to enhance the solubility and dissolution rate of meloxicam, a poorly water-soluble drug (BCS class II). Meloxicam is loaded on commercial and modified halloysite (acidic and alkaline etching, or APTES and chitosan functionalization) via a solution method. Several techniques (XRPD, FT-IR, C solid-state NMR, SEM, EDS, TEM, DSC, TGA) are applied to characterize both HNTs and meloxicam-HNT systems. In all the investigated drug-clay hybrids, a high meloxicam loading of about 40 wt% is detected. The halloysite modification processes and the drug loading do not alter the structure and morphology of both meloxicam and halloysite nanotubes, which are in intimate contact in the composites. Weak drug-clay and drug-functionalizing agent interactions occur, involving the meloxicam amidic functional group. All the meloxicam-halloysite composites exhibit enhanced dissolution rates, as compared to meloxicam. The meloxicam-halloysite composite, functionalized with chitosan, showed the best performance both in water and in buffer at pH 7.5. The drug is completely released in 4-5 h in water and in less than 1 h in phosphate buffer. Notably, an equilibrium solubility of 13.7 ± 4.2 mg/L in distilled water at 21 °C is detected, and wettability dramatically increases, compared to the raw meloxicam. These promising results can be explained by the chitosan grafting on the outer surface of halloysite nanotubes, which provides increased specific surface area (100 m/g) disposable for drug adsorption/desorption.
该研究聚焦于美洛昔康-埃洛石纳米管(HNT)复合材料的合成与表征,以此作为提高美洛昔康(一种难溶性药物,BCS II类)溶解度和溶解速率的可行方法。通过溶液法将美洛昔康负载于商用及改性埃洛石(酸蚀、碱蚀或APTES和壳聚糖功能化)上。应用多种技术(XRPD、FT-IR、C固体核磁共振、SEM、EDS、TEM、DSC、TGA)对HNTs和美洛昔康-HNT体系进行表征。在所有研究的药物-黏土杂化物中,检测到美洛昔康的高负载量约为40 wt%。埃洛石改性过程和药物负载并未改变美洛昔康和埃洛石纳米管的结构与形态,它们在复合材料中紧密接触。发生了弱的药物-黏土和药物-功能化剂相互作用,涉及美洛昔康的酰胺官能团。与美洛昔康相比,所有美洛昔康-埃洛石复合材料的溶解速率均有所提高。用壳聚糖功能化的美洛昔康-埃洛石复合材料在水和pH 7.5的缓冲液中均表现出最佳性能。该药物在水中4-5小时内完全释放,在磷酸盐缓冲液中不到1小时即可完全释放。值得注意的是,在21°C蒸馏水中检测到平衡溶解度为13.7±4.2 mg/L,与未加工的美洛昔康相比,润湿性显著增加。这些有前景的结果可以通过壳聚糖接枝到埃洛石纳米管外表面来解释,这增加了可用于药物吸附/解吸的比表面积(100 m/g)。